Matrix-M™ adjuvant elicits strong humoral and cellular immune responses in clinical influenza trials

download, Matrix-M™ adjuvant, clinical influenza trials
Matrix-MTM (saponin based adjuvant) is not equivalent to or synonymous with:

– ISCOMs (or "classical" ISCOMs)

– MATRIX / ISCOMATRIXTM – CSL Ltd


With 40 nm particles stabilized with cholesterol and phosphplipid, reduced reactogenicity vs previous saponin adjuvants, balanced Th1/Th2 stimulation of antibody and cellular response, and confirmed efficacy and safety in animals and humans; this really is an exciting piece of R&D. GMP material also available.
Matrix-Mâ„¢ Influenza Study Conclusions Phase I Pandemic and Seasonal Elderly demonstrated:

• Safe, excellent tolerability

• Strong HI and VNA immune responses

• Exceeds EMA criteria and non-adjuvanted comparator vaccines

• Induces cross-reactive humoral responses

• Elicits pronounced cellular responses

• Dose-sparing capacity

• Potential to improve clinical efficacy in target populations

Why not download the full presentation and discover more about Matrix-Mâ„¢ adjuvant elicits strong humoral and cellular immune responses in clinical influenza trials:

Phase I seasonal influenza trial in the elderly

Phase I pandemic influenza trial

Combined study data shows excellent safety profile

Dr Anders Kärnell, Chief Medical Officer, Isconova

Download the presentation here >

To learn more about this and the other topics discussed at this event, please click here >

For more updates on the vaccines industry, follow us on Twitter: @vaccinenation or join our LinkedIn group: Vaccine Nation

Leave a Reply

Your email address will not be published. Required fields are marked *